Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia

Persistence of IDH1 or IDH2 mutations in remission bone marrow specimens of patients with acute myeloid leukemia has been observed, but the clinical impact of these mutations is not well known. In this study, we evaluated 80 acute myeloid leukemia patients with known IDH1 R132 or IDH2 R140/R172 muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Ok, Chi Young, Loghavi, Sanam, Sui, Dawen, Wei, Peng, Kanagal-Shamanna, Rashmi, Yin, C. Cameron, Zuo, Zhuang, Routbort, Mark J., Tang, Guilin, Tang, Zhenya, Jorgensen, Jeffrey L., Luthra, Rajyalakshmi, Ravandi, Farhad, Kantarjian, Hagop M., DiNardo, Courtney D., Medeiros, L. Jeffrey, Wang, Sa A., Patel, Keyur P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355476/
https://www.ncbi.nlm.nih.gov/pubmed/30171025
http://dx.doi.org/10.3324/haematol.2018.191148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355476/
https://www.ncbi.nlm.nih.gov/pubmed/30171025
http://dx.doi.org/10.3324/haematol.2018.191148

Ejemplares similares